Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Februar 2020 08:00 ET | Quelle: Applied Molecular Transport

Applied Molecular Transport’s Proprietary Approach to Designing Oral Biologic Therapeutics Published in Tissue Barriers Journal

SOUTH SAN FRANCISCO, Calif., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (AMT), a clinical-stage biopharmaceutical company, today announced the first publication describing...
18. Februar 2020 08:00 ET | Quelle: Applied Molecular Transport

Applied Molecular Transport Presents Preclinical Data on AMT-101, an Oral GI-selective rhIL-10 at European Crohn’s and Colitis Organisation (ECCO)

AMT-101, an oral GI-selective rhIL-10, showed potent activity at the site of disease in the colon in UC model with negligible systemic exposureOnce daily, oral AMT-101 efficiently crossed the...
10. Oktober 2019 08:00 ET | Quelle: Applied Molecular Transport

Applied Molecular Transport Appoints Veteran Biopharmaceutical Executive, Liz Bhatt, to Role as Chief Business and Strategy Officer

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Applied Molecular Transport (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Liz Bhatt to the...
09. September 2019 08:00 ET | Quelle: Applied Molecular Transport

Applied Molecular Transport Debuts with First Patient Dosed in Phase 1b Clinical Trial of AMT-101 in Adults with Ulcerative Colitis

SOUTH SAN FRANCISCO, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Applied Molecular Transport (AMT), a clinical- stage biopharmaceutical company, today announced that the first patient has been dosed...